ExxonMobil and Porsche Expand Motorsports Technology Partnership Into Formula E
6.9.2019 16:00:00 EEST | Business Wire | Press release
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. The new partnership represents ExxonMobil’s first entry into electric motorsports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190906005023/en/
ExxonMobil is expanding its global business and technical partnership with Porsche by teaming with the luxury German automaker on its Formula E series car for the 2019 / 2020 season. (Photo: Business Wire)
Starting from the first race in Saudi Arabia at the end of this year, ExxonMobil will provide Mobil-branded high-performance electric powertrain fluids to Porsche, developed specifically to meet the specialized demands of electric vehicles.
“Our entry into Formula E with Porsche not only represents an expansion to our successful business relationship, but an expansion of a winning partnership in racing,” said Russ Green, vice president, finished lubricants at ExxonMobil. “As Porsche begins to compete and demonstrate the capabilities of its electric vehicle technology, ExxonMobil is engineering a full suite of Mobil-branded lubricants to help the new Porsche Formula E team build on its legacy of racing success around the world. Motorsport provides the ultimate proving ground to continue to develop high-performance lubricants and fluids.”
Vehicles competing in electric motorsports benefit from high-performance lubricant technology that provides specialized advantages needed for the car’s battery pack including electrical conductivity, cooling capabilities and material compatibility.
“As a key technical partner of more than 20 years, no other lubricant supplier understands the Porsche performance philosophy like ExxonMobil,” said Fritz Enzinger, vice president, Porsche Motorsport. “ExxonMobil has not only been a valuable partner for our commercial business, but an important teammate in our pursuit of wins and championships from Sebring to Le Mans. They were a natural addition to our Formula E team as we enter an exciting new era of racing for Porsche.”
The new technical partnership joins ExxonMobil’s existing roster of global motorsports activities with Porsche including the World Endurance Championships, IMSA WeatherTech SportsCar Championship, Porsche Mobil 1 Supercup, Porsche Carrera Cup and numerous customer racing activities around the world.
About ExxonMobil
ExxonMobil, the largest publicly traded international oil and gas company, uses technology and innovation to help meet the world’s growing energy needs. ExxonMobil holds an industry-leading inventory of resources, is one of the largest refiners and marketers of petroleum products, and its chemical company is one of the largest in the world.
About ExxonMobil in Motorsports
Racing provides ExxonMobil and its lubricants and fuels brands the ultimate testing ground to improve the technology in our range of oil, lubricants and fuels. Each race season, our advanced products go to work to help improve vehicle performance and efficiency. ExxonMobil products serve as the lubricant of choice for many of the world’s top race teams competing in highly demanding motorsports series. The knowledge we gain through these partnerships helps our scientists and engineers push the boundaries in developing cutting-edge technologies.
ExxonMobil remains proud partners with Aston Martin Red Bull Racing, Stewart-Haas Racing in NASCAR’s Sprint Cup Series; Porsche, Bentley and TOYOTA GAZOO Racing in the FIA World Endurance Championship; Corvette Racing, Porsche North America, Lexus and Acura/Caterpillar in the IMSA WeatherTech SportsCar Championship; and numerous teams competing in series around the world.
For more information about ExxonMobil and its brands, visit www.exxonmobil.com or follow us on Twitter www.twitter.com/exxonmobil.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190906005023/en/
Contact information
Media Relations
832-625-4000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom